GSK241227P00036000 Option on GlaxoSmithKline PLC ADR

GSK Stock  USD 34.47  0.74  2.10%   
GlaxoSmithKline PLC's latest option contracts expiring on 2024-12-13 are carrying combined implied volatility of 0.14 with a put-to-call open interest ratio of 0.35 over 19 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on 2024-12-13. The total put volume is at 35.0, with calls trading at the volume of 35.0. This yields a 0.14 put-to-call volume ratio.

Open Interest Against 2024-12-13 Option Contracts

The chart above shows GlaxoSmithKline PLC's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. GlaxoSmithKline PLC's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for GlaxoSmithKline PLC's option, there is no secondary market available for investors to trade.

In The Money vs. Out of Money Option Contracts on GlaxoSmithKline PLC

Analyzing GlaxoSmithKline PLC's in-the-money options over time can help investors to take a profitable long position in GlaxoSmithKline PLC regardless of its overall volatility. This is especially true when GlaxoSmithKline PLC's options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money GlaxoSmithKline PLC's options could be used as guardians of the underlying stock as they move almost dollar for dollar with GlaxoSmithKline PLC's stock while costing only a fraction of its price.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

GlaxoSmithKline PLC ADR In The Money Call Balance

When GlaxoSmithKline PLC's strike price is surpassing the current stock price, the option contract against GlaxoSmithKline PLC ADR stock is said to be in the money. When it comes to buying GlaxoSmithKline PLC's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on GlaxoSmithKline PLC ADR are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

GlaxoSmithKline Current Options Market Mood

GlaxoSmithKline PLC's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps GlaxoSmithKline Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Open Interest

Put-to-Call Volume

Most options investors, including buyers and sellers of GlaxoSmithKline PLC's calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. GlaxoSmithKline PLC's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.

Rule 16 of the current GlaxoSmithKline contract

Base on the Rule 16, the options market is currently suggesting that GlaxoSmithKline PLC ADR will have an average daily up or down price movement of about 0.00875% per day over the life of the 2024-12-13 option contract. With GlaxoSmithKline PLC trading at USD 34.47, that is roughly USD 0.003016. If you think that the market is fully incorporating GlaxoSmithKline PLC's daily price movement you should consider buying GlaxoSmithKline PLC ADR options at the current volatility level of 0.14%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
  
Purchasing GlaxoSmithKline PLC options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" GlaxoSmithKline calls. Remember, the seller must deliver GlaxoSmithKline PLC ADR stock to the call owner when a call is exercised.

GlaxoSmithKline PLC Option Chain

When GlaxoSmithKline PLC's strike price is surpassing the current stock price, the option contract against GlaxoSmithKline PLC ADR stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
GlaxoSmithKline PLC's option chain is a display of a range of information that helps investors for ways to trade options on GlaxoSmithKline. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for GlaxoSmithKline. It also shows strike prices and maturity days for a GlaxoSmithKline PLC against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone.
Open IntExpirationCurrent SpreadLast Price
Call
GSK Option Call 13-12-2024 28102024-12-130.0 - 0.06.83In
Call
GSK Option Call 13-12-2024 29152024-12-130.0 - 0.05.42In
Call
GSK Option Call 13-12-2024 33382024-12-130.0 - 0.02.65In
Call
GSK Option Call 13-12-2024 345542024-12-130.0 - 0.01.4In
Call
GSK Option Call 13-12-2024 351452024-12-130.0 - 0.00.54Out
Call
GSK Option Call 13-12-2024 365242024-12-130.0 - 0.00.13Out
Call
GSK Option Call 13-12-2024 372102024-12-130.0 - 0.00.1Out
Call
GSK Option Call 13-12-2024 38142024-12-130.0 - 0.00.02Out
Call
GSK Option Call 13-12-2024 3912024-12-130.0 - 0.00.16Out
 Put
GSK Option Put 13-12-2024 2332024-12-130.0 - 0.00.05Out
 Put
GSK Option Put 13-12-2024 3052024-12-130.0 - 0.00.1Out
 Put
GSK Option Put 13-12-2024 3132024-12-130.0 - 0.00.12Out
 Put
GSK Option Put 13-12-2024 32122024-12-130.0 - 0.00.3Out
 Put
GSK Option Put 13-12-2024 332862024-12-130.0 - 0.00.05Out
 Put
GSK Option Put 13-12-2024 341102024-12-130.0 - 0.00.07Out
 Put
GSK Option Put 13-12-2024 351082024-12-130.0 - 0.00.2In
 Put
GSK Option Put 13-12-2024 3662024-12-130.0 - 0.00.67In
 Put
GSK Option Put 13-12-2024 3812024-12-130.0 - 0.04.45In
 Put
GSK Option Put 13-12-2024 4012024-12-130.0 - 0.06.6In

GlaxoSmithKline PLC Market Cap Over Time

   Market Cap   
       Timeline  

GlaxoSmithKline Total Stockholder Equity

Total Stockholder Equity

14.01 Billion

At this time, GlaxoSmithKline PLC's Total Stockholder Equity is quite stable compared to the past year.

GlaxoSmithKline PLC Corporate Directors

Lynn ElsenhansIndependent Non-Executive DirectorProfile
Harry DietzNon-Executive Independent Director, Scientific and Medical ExpertProfile
Charles BancroftNon-Executive Independent DirectorProfile
Vivienne CoxIndependent Non-Executive Director and Workforce Engagement DirectorProfile
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.28)
Dividend Share
0.61
Earnings Share
1.55
Revenue Per Share
15.38
Quarterly Revenue Growth
(0.02)
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.